

DB-ALM Protocol n° 121 : EpiDerm™ Phototoxicity Assay

Phototoxicity

This test is designed to detect the phototoxic potential of a chemical by using a three dimensional human epidermis model.

Objective & Application

| | |
|---------------------|--|
| TYPE OF TESTING | : Replacement |
| LEVEL OF ASSESSMENT | : Toxic potential, toxic potency |
| PURPOSE OF TESTING | : Safety, classification and labelling |

Reconstituted skin models and epidermis models have shown to be able to predict both, photoirritancy (Edwards et al., 1994; Rouget et al., 1994; Liebsch et al., 1995), as well as the photoprotective action of sunscreens (Rouget et al., 1994). Since the EpiDerm™, a three dimensional model, allows application of test materials to the air exposed surface (stratum corneum), it mimics the *in vivo* situation and thus may allow to predict phototoxic potency of the test materials applied in usage concentrations.

This test is therefore indicated for its use in testing strategies based purely on *in vitro* tests, which may allow to assess safety or phototoxic potency also of formulations (e.g. emulsions, suspensions).

Furthermore, a phototoxicity test using human skin models may be useful for risk benefit analysis of dermal pharmaceuticals.

Résumé

Phototoxicity (photoirritation) is defined as acute toxic response that is elicited after the first exposure of skin to certain chemicals and subsequent exposure to light, or that is induced similarly by skin irradiation after systemic administration of a chemical substance.

The present test is designed to detect the phototoxic potential of a chemical by using a three-dimensional human epidermis model, MatTek's EpiDerm System (Klausner et al., 1995; Perkins et al., 1996), which allows to handle also formulations in contrast to cell based tests.

The mechanistic basis of the test is strong because skin is the target organ for phototoxicity. By using an appropriate test design (chemical dose-response in the presence and absence of a non-cytotoxic UVA-vis radiation) only chemical induced phototoxic reactions will be detected.

The test is based upon a comparison of the cytotoxicity of a chemical when tested with and without additional exposure to a non toxic dose of vis light. Cytotoxicity is determined as reduction of mitochondrial conversion of MTT to formazan (Mosmann, 1983), determined one day after chemical treatment and UVA exposure.

Experimental Description

Endpoint and Endpoint Measurement:

TISSUE VIABILITY: determined by a reduction in mitochondrial dehydrogenase activity, measured by formazan salt production from MTT. It is expressed as % of the negative control

Endpoint Value:

Experimental System(s):

RHE EpiDerm™: The reconstructed human epidermal model EpiDerm™ (EPI-200, MatTek, Ashland, USA and MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia) grown from normal human-derived epidermal keratinocytes, which have been cultured to form a multilayered highly differentiated model of the human epidermis. It consists of organised basal, spinous and granular layers, and a multilayered stratum corneum containing intercellular lamellar lipid layers arranged in patterns analogous to those found *in vivo*. The EpiDerm™ tissues (surface 0.63 cm²) are cultured on specially prepared cell culture inserts and shipped world-wide as kits, containing 12, 18 or 24 tissues on shipping agarose together with the necessary amount of culture media and handling plates.

Basic Procedure

On day of receipt EpiDerm™ tissues are stored over night in a refrigerator. Next day, at least one hour before starting the assay, tissues are transferred to 6-well plates with assay medium and the medium is exchanged. Then, 5 concentrations of the test material (dissolved in H₂O or oil or suspended in oil) are topically applied onto 2 tissues per concentration (i.e. 1 vehicle control + 5 concentrations = 12 tissues). A second set of 12 tissues is treated identically. Plates are incubated over night. Next day, one set of tissues is exposed to 6 J/cm² UVA (**+UVA part of the test**) and the other set is kept in the dark for the same period (**-UVA part of the test**).

Tissues are then rinsed with phosphate buffered saline (PBS) to remove test material, transferred to new 6 well plates with fresh medium and incubated over night. Next day, assay medium is replaced by MTT-medium and tissues are incubated for 3 hours with MTT. Tissues are then rinsed with PBS, and the formazan is extracted with Isopropanol. Optical density is determined at 540/570 nm in a plate spectrophotometer and cell viability is calculated for each tissue as % of the corresponding vehicle control either irradiated or unirradiated.

*MatTek's EpiDerm System consists of normal, human-derived epidermal keratinocytes which have been cultured to form a multilayered, highly differentiated model of the human epidermis. It consists of organised basal, spinous and granular layers, and a multi-layered stratum corneum containing intercellular lamellar lipid layers arranged in patterns analogous to those found *in vivo*. The EpiDerm tissues (surface 0.6 cm²) are cultured on specially prepared cell culture inserts (Millicells®, 10 mm \varnothing) and shipped worldwide as kits, containing 24 tissues on shipping agarose.

Data Analysis/Prediction Model

For each concentration of test chemical, the mean OD of the tissue couple treated with this concentration is determined and expressed as relative percentage of viability of the untreated control. A chemical is predicted to have a phototoxic potential, if one or more test concentrations of the +UVA part of the experiment reveal a decrease in viability exceeding 30% when compared with the identical concentrations of the -UVA part.

For details see the section 3. "**Prediction Model**" of the attached standard operating procedure.

Test Compounds and Results Summary

10 test chemicals have been tested in the Prevalidation Study of the EpiDerm™ Phototoxicity Test: 5 photoirritants and 5 non photoirritants.

Discussion

The EU/COLIPA Validation Study (Spielmann et al., 1995; Liebsch et al., 1994) has shown that the phototoxic potential of chemicals can be correctly predicted in a specially designed cytotoxicity assay, by using cell culture monolayers: the 3T3-NRU-phototoxicity test. Since the phototoxic potential of a chemical predicted using a cellular system may not be relevant when topically applied to the skin at low concentrations (e.g. in a formulation), there is a need for adjunct tests.

Reconstituted skin models and epidermis models have shown to be able to predict both, photoirritancy (Edwards et al., 1994; Rouget et al., 1994; Liebsch et al., 1995; Api, 1997), as well as the photoprotective action of sunscreens (Rouget et al., 1994).

In addition, skin models can handle formulations (e.g. emulsions, suspensions) which the 3T3 test cannot handle.

Thus, in a testing strategy which is based purely on *in vitro* tests, there is a need to combine the basic 3T3 NRU PT with other *in vitro* tests, which may allow to assess safety or phototoxic potency of formulations. Skin models can handle formulations (e.g. emulsions, suspensions) which the 3T3 test cannot handle.

The EpiDerm™ phototoxicity test was chosen for prevalidation since production of the full human *in vitro* model SKIN² was stopped by the manufacturer in October 1996, which obtained promising results in the blind trial of an EU/COLIPA validation project of "*In vitro* photoirritant" tests (Liebsch et al., 1997). The Skin² methodology has been adopted to the human *in vitro* model of the reconstituted human epidermis EpiDerm™ (MatTek, Ashland, USA).

The only limitations are the facts that the epidermal model has no fibroblasts and that the endpoint is reduction of viability instead of measuring mediators of inflammation. However, since all mechanisms of phototoxicity will finally lead to cell damage, assessment of the inflammation response may not be important.

Status

The outcome of the prevalidation study confirmed the expected high predictivity and robustness of the EpiDerm test: only one positive chemical was not detected as phototoxin and none of the negative chemicals overpredicted as phototoxin.

A COLIPA Task Force on "*In vitro* Photoirritation" will define the role of the assay as an adjunct in an *in vitro* phototoxicity test strategy.

Last update: 6 July 1999

PROCEDURE DETAILS, 5 November 1997***EpiDerm™ Phototoxicity Assay
DB-ALM Protocol n° 121**

Note: the protocol presents the standard operation procedure used in the Prevalidation of the EpiDerm™ Phototoxicity Test. It should be noted that this protocol might need to be modified in light of experience gained in the study.

* A proposed update of the SOP has been sent to the person responsible for the method for review and can be provided on request. As soon as new information will become available this version of the protocol will be updated.

Contact Details

Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET)
Federal Institute for Risk Assessment (BfR)
Diedersdorfer Weg 1
Berlin D-12277
email: zebet@bfr.bund.de

1. Materials**1.1 MATERIALS, not provided with the kits:****1.1.1 Laboratory aids**

| | |
|--|---|
| Sterile, blunt-edged forceps | for transferring inserts |
| 6-well tissue culture plates (in addition to those provided) | if, instead of replacing media inserts are transferred to new plates with media |
| 24-well culture plates (in addition to those provided) | for UVA irradiation, if not performed in 6-well plates |
| 96-well plates (flat-bottom) | for OD reading in plate spectrophotometer |
| Sterile disposable pipette tips | |
| 5 Beakers á 50 ml | |
| sterile, capped glass or plastic test tubes | for preparing the concentration series |
| Finn chamber filter pads, Ø 8 mm, sterilised HERMAL, Scholtzstr. 3, D-21465 Reinbek, Purchase Order No.: D 9503 | for application of test materials dissolved or suspended in oil |
| Repeat pipetter (2 ml) | for adding the extractant solution |
| Positive displacement pipettes (20 µL, 50µl) | for application of viscous test materials |
| adjustable Pipet (100 µl) | for pipetting the concentration series |
| adjustable Pipet (200 µl) | for pipetting the concentration series |
| adjustable Pipet (1000 µl) | for medium change |

1.1.2 Technical Equipment

| | |
|--|--|
| Bunsen burner or autoclave | for sterilising forceps |
| 37 °C humidified incubator with 5% CO ₂ , | for incubating tissues prior to and during assays |
| vacuum source/trap | for aspirating solutions |
| laminar flow hood | for transferring tissues under sterile conditions and for application of test materials. |
| 37 °C water bath | for warming up Assay Medium, PBS etc. |
| Laboratory balance | for preparing concentration series |
| 96-well Spectrophotometer (Plate-Reader) equipped with filter 570 nm or 540 nm | for reading optical density at 570 nm |
| Shaker for cell culture plates | for extraction of formazan |
| Laboratory centrifuge 1500 x g | for centrifugation of MTT medium |
| Vortex mixer | for keeping test suspensions homogeneous during preparation of the concentration series |
| electric homogeniser | for preparing test chemical suspensions in oil |

1.1.3 UVA-vis Irradiation equipment

| | |
|---|---|
| UV-sun simulator type SOL 500 or SOL 3 | Dr. K.Hönle GmbH, Fraunhoferstr. 5, D-82152 Martinsried, Germany Contact: Dr. G. Schmid (Tel.: +49-89-856 08-0 Fax: +49-89-856 08-48 |
| Any appropriate, adjustable and stable tripod | For the fixation of the SOL 500 |
| UVA-meter, type No. 37, Dr. Hönle | For everyday check of calibration |
| UVA-meter, type No. 37, Dr. Hönle | Use only as a reference in case of unexpected readings with the everyday radiometer |
| Filter, type H1, Dr. Hönle | Use to cut-off emitted UVB |

1.1.4 Solutions, Reagents

| | |
|--|--|
| Sesame oil (USP/EP/DAB grade) source: pharmacy | Vehicle for test materials |
| H ₂ O Aqua Pur (Millipore®), or distilled H ₂ O | Vehicle for test materials |
| PBS with Ca ⁺⁺ and Mg ⁺⁺ : ~500ml per test (e.g. Gibco # 14040) | For rinsing-off test materials after irradiation |

1.1.5 Computer software

| | |
|---|---|
| (MS Windows software) for Plate spectrophotometer | Software must be able to export data |
| MS Excel 5.0 | For and data analysis in the Data Spreadsheet |

1.2 EPI-200 KIT COMPONENTS

Examine all kit components for integrity. If there is a concern call MatTek Corporation immediately (Mitch Klausner, Tel. +1-508-881-6771, Fax +1-508-879-1532).

| | | |
|----------|----------------------------------|--|
| 1 | Sealed 24-well plate | Contains 24 inserts with tissues on agarose |
| 2 | 24-well plates | Use for MTT assay and formazan extraction |
| 4 | 6-well plates | Use for pre-incubation (and assay) |
| 1 bottle | Serum-Free Assay Medium | DMEM-based medium |
| 1 bottle | Maintenance Medium | Do not use in the present assay |
| 1 bottle | PBS Rinse Solution (100 ml) | Use for rinsing the inserts in MTT assay |
| 1 vial | 1% Triton X-100 Solution (10 ml) | Skin irritant reference chemical Do not use in present assay |
| 1 | MTT Assay Protocol | steps are included in the present SOP |

1.3 MTT-100 Assay Kit Components

| | | |
|-----------------|-----------------------------------|-------------------------------------|
| 1 vial, 2 ml | MTT concentrate | |
| 1 vial, 8 ml | MTT diluent | For diluting MTT concentrate |
| 1 bottle, 60 ml | Extractant Solution (Isopropanol) | For extraction of formazan crystals |

2. Methods

2.1 EXPIRATION AND KIT STORAGE

Epi-200 kits are shipped from Boston on Monday; make sure that they are arriving in the laboratory on Tuesday. Upon receipt of the EpiDerm tissues, place the sealed 24 well plates and the assay medium into the refrigerator (4°C). Place the MTT concentrate containing vial in the freezer (- 20°C) and the MTT diluent in the refrigerator (4°C).

| part # | description | conditions | shelf life |
|---------|-------------------|-------------------|--------------|
| EPI-200 | EpiDerm™ cultures | Refrigerate (4°C) | until Friday |
| EPI-100 | assay medium | Refrigerate (4°C) | 7 days |
| MTT-099 | MTT diluent | Refrigerate (4°C) | 7 days |
| MTT-100 | MTT concentrate | Freeze (- 20°C) | 2 month |

Record lot numbers of all components and transfer lot/production label on sealed tray onto the Methods Documentation Sheet (MDS see **ANNEX B**).

Note: Since testing starts on Wednesday, irradiation on Thursday, MTT assay on Friday, do not order more Epi-200 kits per week than can be dosed or irradiated on one day, respectively. This does not hold for US labs: if they receive kits on Tuesday before 12:00 the test can be started.

2.2 CALIBRATION OF THE SOLAR SIMULATOR

Note: New metal halide burners should be burned for ~100 hrs prior to first use to achieve a stable emittance. According to Dr Hoenle the burner has a shelflife (in which the spectrum is stable) of at least 800 hrs. Recording of lamp usage hours is, therefore, recommended. Extended use is only acceptable if the emitted energy spectrum can be checked.

1. Mount the SOL 500 / SOL 3 lamp, equipped with a H1-filter, on any appropriate stable tripod allowing fine-adjustment of the exposure distance.
2. Adjust SOL 500 / SOL 3 to a distance of about 60 cm.
3. Switch the Lamp on, wait at least 15 minutes and measure irradiance **through the lid of a cell culture plate** using the calibrated UV radiometer (type 37, Dr. Hönle), equipped with an UVA-sensor of the same serial number.
4. Adjust distance of SOL 500 / SOL 3 to achieve a UVA irradiance of **1.7 mW/cm²** (The resulting dose will be 1 J/cm² per 10 min. exposure time)
5. According to the number of plates to be exposed concurrently, check the exposure area for equal distribution of irradiance: a range of **1.6 - 1.8 mW/cm²** is acceptable.
Important: A maximum difference of **1.5 and 1.9 mW/cm²** can be accepted, if positions of the plates with low and high irradiance are changed after half time of the irradiation (30 minutes) is reached (like chess castling).

Calibration of the SOL 500 / SOL 3 shall be checked as described above each time before performing a phototoxicity assay. In case measurements with the UV radiometer reveal unexpected results, either the metal halide burner may

have reached the end of its shelflife, or the radiometer is de-calibrated due to various reasons. In this case, a second reference radiometer of the same type and calibration, which has not been handled every day and kept in the dark shall be used for cross check.

2.3 QUALITY CONTROLS

2.3.1 UVA Sensitivity of the Epi-200 Tissues

Note: A UVA sensitivity experiment should be performed once the test is newly set up in a laboratory. If UVA sensitivity of the tissues is within the acceptance range this type of experiment should be repeated in greater intervals (e.g. once every 6 months).

1. Incubate 24 tissues (37°C, 5 % CO₂) for at least 1 hr in 6-well plates with 0.9 ml assay medium /well to allow release of metabolites and debris accumulated during the shipment.
2. Adjust irradiance of the SOL 500 / SOL 3 to 1.7 mW/cm² (measure through plate lid !)
3. For UV irradiation, transfer 21 tissues to a 24-well plate filled with 0.3 mL assay medium per well.
4. Prepare a 24 well plate with 0.3 ml assay medium per well and transfer the 3 tissues serving as non-irradiated control. Place this plate in a dark box at room temperature.
5. Start irradiation of the 21 tissues through the lid of the plate. Use a fan to prevent H₂O condensation under the lid. Every 30 minutes (= 3 J/cm²) transfer 3 tissues from the irradiation site to the dark box. The resulting dose series is 3, 6, 9, 12, 15, 18, 21 J/cm².
6. Incubate tissues over night (18 - 24 hrs.) at 37°C, 5 % CO₂, 90 % humidity
7. Determine tissue viability according to 2.5 "**Experimental Procedure**". Compared to the non irradiated tissues (100 % viability) up to 6 J/cm² (= 60 minutes) there shall be no reduction of viability exceeding 20%. The historical ID₅₀ UVA is in the range of ~12 - 18 J/cm² (see ANNEX F).

2.3.2 Negative Control

The **absolute OD** of the negative control tissues in the MTT-test (see section 2.5 "**Experimental Procedure**") is an indicator of tissue viability obtained in the testing laboratory after shipping procedure and under specific conditions of the assay.

*Tissue viability is meeting the acceptance criterion if the mean OD of the two negative control tissues (determined without reference filter) is **OD** ≥ 0.8.*

2.3.3 Positive Control: Chlorpromazine (CPZ)

For the present study, it is not necessary to include a positive control into each phototoxicity test as this reduces the number of concentrations of the test chemical. When the assay is newly established perform a full experiment with five concentrations of **Chlorpromazine** (dissolved in H₂O) ranging from 0.001% up to 0.1%. Repeat this test on a regular basis.

A dose dependent reduction of cell viability occurring only in the UVA-irradiated tissues, shall be observed between 0.00316% and 0.0316% (see **ANNEX D**).

Note: If, in other studies, CPZ shall be included in each assay, use 0.316%.

2.3.4 Maximum inter tissue viability difference of tissue couples

The new spreadsheet calculates differences in viability between tissue couples that are treated identically. According to the historical data base of ZEBET the mean difference between untreated tissue duplicates is $9\% \pm 7\%$ (S.D.).

A difference > 30% (i.e. exceeding the 99% confidence interval) between two tissues treated identically should be regarded as a rejection criterion, and re-testing of the chemical is recommended if the resulting viability is near to the classification cut-off.

2.4 TEST SAMPLE PREPARATION AND TEST CONCENTRATIONS

According to their solubility, chemicals are applied either as solution in **water**, or as solution or suspension in **sesame oil**.

| DESCRIPTIVE TERM | RANGE OF SOLUBILITY | % (w/v) | CATEGORY |
|-----------------------|--------------------------|---------|----------|
| very soluble | > 1000 mg/ml | >100.00 | 1 |
| freely soluble | > 100 mg/ml - 1000 mg/ml | >10.00 | 2 |
| soluble | > 30 mg/ml - 100 mg/ml | >3.00 | 3 |
| sparingly soluble | > 10 mg/ml - 30 mg/ml | >1.00 | 4 |
| slightly soluble | > 1 mg/ml - 10 mg/ml | >0.10 | 5 |
| very slightly soluble | > 0.1 mg/ml - 1 mg/ml | >0.01 | 6 |
| practically insoluble | 0.1 mg/ml and lower | <0.01 | 7 |

As a basic recommendation, poorly water soluble test materials (category 5-7) should be tested dissolved or suspended in sesame oil. Water soluble test materials (category 1-4) shall be tested dissolved (!) in water.

If suspensions are tested use appropriate techniques for preparing e.g. a homogeniser, Vortex or Sonicator).

2.4.1 Concentration series

Prepare five concentrations of the test material. Where possible, the highest concentration of a test material should show cytotoxicity in non-irradiated tissues. Since many test chemicals are likely to absorb UV they can act as UV-filter. Therefore, the highest test concentration should **not exceed 10%**.

If there is no information on skin toxicity of the test material, start with the following concentration series:

| Vehicle | % (w/v) |
|---------|---------|---------|---------|---------|---------|
| Oil | 10 | 3.16 | 1 | 0.316 | 0.1 |
| Water | 1 | 0.316 | 0.1 | 0.0316 | 0.01 |

Note: According to ZEBET's experience, the series for oil fits for many test materials. Materials solved in water pass the stratum corneum more quickly. If they are, in addition, highly cytotoxic the concentration series may have to be shifted to a lower range in a second experiment.

2.4.2 Application of test sample

Note: To be as close as possible to the human in vivo test and to achieve a constant application area, a patch technique was developed using 8 mm Ø paper disks (normally used in Finn chambers for human patch tests). However, experiments performed at P&G, Beiersdorf AG and ZEBET revealed

that the patch technique is only an improvement when oil is used as vehicle, since the pads soaked with aqueous solutions dried during over night exposure. Therefore, preparations in **oil** are applied at **20 µl plus pad** whereas solutions in **H₂O** are applied at **50 µl without pad**

- **Solutions in H₂O:** Apply **50 µl** to the EpiDerm™ tissue and gently spread.
- **Solutions in oil:** Soak the Finn pad by pipetting **20 µl** to the pad and put it on the tissue.
- **Suspensions in oil and other formulations:** Soak "bottom" of Finn pad (tissue contact site) with 20 µL, turn the pad around and put it on the tissue.

2.5 EXPERIMENTAL PROCEDURE

Day before testing

Upon receipt of EpiDerm™ kits (Europe: Tuesday afternoon), place assay medium and sealed 24-well plates containing tissues on agarose into refrigerator (4°C ± 2°C). Place the vial containing the MTT concentrate in the freezer (-20°C ± 5°C).

First day of testing

Note: It is essential that, before the test is started, tissues are incubated for at least 1 hr in assay medium into which they can release metabolites and debris accumulated during the shipment. This medium has to be replaced before the assay is started. For this important incubation 6-well plates have to be used with 0.9 ml medium per well. Alternative techniques (e.g. use of 24 well plates or incubation of all insets in a petri dish) had to be disapproved during this study).

1. Prewarm assay medium in a 37°C waterbath
2. Pipet 0.9 ml of assay medium into each well of sterile 6-well plates
3. Using sterile techniques transfer the inserts (be sure to remove all transport agar) into 6-well plates containing prewarmed assay medium. Any air bubbles trapped underneath the inserts should be released. Incubate for a minimum of 1 hr at 37°C, 5% CO₂. Record incubation time in the MDS .
4. While tissues are in the incubator, for each test chemical, prepare a series of five concentrations according to "Record preparations" in the MDS.
5. After (at least) 1 hr incubation transfer inserts into new 6-well plates prepared with new 0.9 ml assay medium per well and prewarmed in the incubator .
6. Per each test chemical use one EpiDerm™ kit (24 tissues): Twelve tissues are used in the **(-UVA)cytotoxicity** part and 12 in the **(+UVA)phototoxicity** part of the test. Both parts of the test are dosed **identically**: Apply vehicle control (VC) plus 5 concentrations of the test chemical (C1 -C5), each on tissue duplicates according to **2.4.2"Application of Test Sample"**. Mark **lids and plates** to prevent from transposition errors.

| |
|---------------|
| + UVA Plate 1 |
|---------------|

| |
|---------------|
| + UVA Plate 2 |
|---------------|

| | | | | | |
|----------------------|-----|-----|----------------------|-----|-----|
| VC | C 1 | C 2 | C 3 | C 4 | C 5 |
| VC | C 1 | C 2 | C 3 | C 4 | C 5 |
| - UVA Plate 1 | | | - UVA Plate 2 | | |
| VC | C 1 | C 2 | C 3 | C 4 | C 5 |
| VC | C 1 | C 2 | C 3 | C 4 | C 5 |

Note: Covering the plate with self adhesive plastic film to prevent from toxic evaporation into neighbour wells is, in general, not necessary in this test. To be on the safe side, position the lowest concentration (C1) beside the vehicle control (VC).

7. Once all tissues have been dosed, cover the plates with the lids and incubate over night (**18-24 hrs**) at 37°C, 5% CO₂.

Second day of testing

1. Remove 6-well plates from the incubator. Remove application pads. Irradiate (**+UVA**)-plates (covered with lids) for **60 min** with **1.7 mW/cm² (=6 J/cm²)** at room temperature. Ventilate with fan to prevent condensation under the lid. Place (**-UVA**)-plates in the dark at room temperature.
2. While tissues are irradiated, prepare appropriate amount of new 6-well plates with 0.9 ml of fresh assay medium per well and prewarm in the incubator.
3. After UVA irradiation is completed, use wash bottle with sterile PBS and rinse each insert of the (**+UVA**) plates and (**-UVA**) plates. Then transfer all inserts to the new plates prepared in **2**.
4. Incubate (**+UVA**)- and (**-UVA**) plates over night (18-24 hrs) at 37°C, 5 % CO₂.

Third day of testing

1) Prepare MTT medium: than MTT concentrate in a water bath and dilute with MTT diluent. Spin down (300´ g, 5 min) to remove any precipitate. Prewarm MTT medium (water bath) to 37°C.

2) For each test material prepare one 24-well plate with 300 µl prewarmed MTT medium per well. Label plates (lid and bottom) and transfer tissue inserts according to the plate design given below. Any air bubbles trapped underneath the inserts should be released.

| | | | | | | |
|----|-----|-----|-----|-----|-----|-------------|
| VC | C 1 | C 2 | C 3 | C 4 | C 5 | +UVA |
| VC | C 1 | C 2 | C 3 | C 4 | C 5 | +UVA |
| VC | C 1 | C 2 | C 3 | C 4 | C 5 | -UVA |

| | | | | | | |
|----|-----|-----|-----|-----|-----|------|
| VC | C 1 | C 2 | C 3 | C 4 | C 5 | -UVA |
|----|-----|-----|-----|-----|-----|------|

Note: Deviations from 3 hour time for MTT incubation will result in different MTT readings. For consistency it is recommended that 3 hour MTT incubation time be adhered very strictly.

3) Incubate 24 well plate 3 hours (37°C, 5 % CO₂). Record start and stop time for MTT incubation in the MDS.

4) After incubation aspirate MTT medium (gently using a suction pump), refill wells with PBS and aspirate PBS. Repeat the procedure twice and make sure tissues are dry after the last aspiration. Transfer inserts to new 24 well plates.

5) For formazan extraction immerse the inserts by gently pipetting 2 ml extractant solution (isopropanol) into each insert. The level will rise above the upper edge of the insert, thus completely covering the tissue from both sides.

6) Seal the 24 well plate (e.g. with a zip bag) to inhibit isopropanol evaporation. Record start time of extraction in the MDS. Extract 2 hrs with shaking (~120 rpm) at room temperature.

7) After formazan extraction period is complete pierce the inserts with an injection needle (~ gauge 20 / 0.9 mm Ø) and allow the extract to run into the well from which the insert was taken. Afterwards the insert can be discarded. Place the 24-well plates on a shaker for 15 minutes until solution is homogeneous in colour.

8) Per each tissue transfer 3x200µl aliquots* of the blue formazan solution into a 96-well flat bottom microtiter plate. For the 96 well plate, use exactly the plate design given below as this configuration is used in the EXCEL data spreadsheet. Read OD in a plate spectrophotometer at **570 nm, without reference filter.**# Alternatively, ODs can be read at **540 nm**.

* **Note:** In contrast to normal photometers, in plate readers pipetting errors influence the OD. Therefore, 3 formazan aliquots shall be taken from each tissue extract. In the data sheet these 3 aliquots will be automatically reduced to one value by calculating the mean of the three aliquots. Thus, for calculations from each single tissue only one single mean OD-value is used.

Note: Readings are performed without reference filter, since the "classical" reference filter often used in the MTT test (630 nm) is still within the absorption curve of formazan. Since filters may have a ± tolerance in some cases the reference filter reduces the dynamics of the signal (OD) up to 40%.

Fixed 96 well-plate design (for OD reading in plate photometer, 3 aliquots per tissue)

| | | | | | | | | | | | | |
|----|----|----|----|----|----|----|----|----|----|----|----|------|
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 | +UVA |
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 | |
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 | -UVA |

| | | | | | | | | | | | |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 |
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 |
| VC | VC | C1 | C1 | C2 | C2 | C3 | C3 | C4 | C4 | C5 | C5 |
| tissue 1 | tissue 2 |

2.6 DOCUMENTATION

2.6.1 Method Documentation Sheet, MDS

The MDS allows to check the correct set up, calibration and function of the equipment as well as correct weights, applications etc. The MDS is designed as a paper document "in the spirit of GLP". **Per each kit, make a hardcopy of the MDS, fill in and sign the requested information, starting the day prior to testing and ending after the test has been conducted.**

Note (1): If several tests are performed per week, pipette verification (weighing H₂O on a balance) is only necessary once at the beginning of each week. Nevertheless, if **adjustable** pipettes are used the correct adjustment shall be checked and recorded in the MDS before each test.

2.6.2 Data Spreadsheet

The MS EXCEL 5.0 spreadsheet P-SPREAD.XLS is provided by ZEBET. Data files of optical densities (ODs) generated by the microplate reader are **copied** from the reader software to the **Windows Clipboard** and then **pasted** into the first map of the EXCEL spreadsheet in the fixed 96-well format given above (**Note:** Only 72 wells of the 96 wells are used!).

P-SPREAD.XLS consists of **two** maps, IMPORT, and SPREAD. The first map (*Import*) is used for pasting OD values (cursor position: **A20!**). The second map (*Spread*) does the calculations and provides a column graph of the results. In addition, entry all information requested (tissue lot-no., test material codes, date...) into this map.

In Phase III of the prevalidation study test chemicals are coded by BIBRA with a four digit code. To allow an easy allocation of the XLS files for statistical analysis after codes are broken, use the following file names **PGXXXX-Y.XLS** or **BDXXXX-Y.XLS** or **ZEXXXXX-Y.XLS** where XXXX stands for the 4-digit code number and Y stands for the number of the test run.

3. Prediction Model

The rules used to transform quantitative or qualitative data of a toxicological test into a prediction of a toxic potential or potency are called prediction model.

The prediction model is based on analysis of historical data of the maximum possible difference in the viability of identically treated EpiDerm™ tissues according to which any difference exceeding 30% has to be regarded significant ($p < 0.001$). Since the UVA irradiation has no cytotoxic effect itself, a phototoxic activity can be predicted if viability of tissues treated with identical test chemical concentrations differs by more than 30% in the irradiated and the non irradiated part of the test.

For each concentration of a test chemical, the mean OD of the tissue couple

treated with this concentration is determined and expressed as relative percentage viability of the untreated vehicle controls. Identical calculations are performed for the (+UVA) part of the test and the (-UV) part of the test.


A chemical is predicted to have a phototoxic potential if one or more test concentrations of the (+UVA) part of the experiment reveal a decrease in viability **exceeding 30%** when compared with identical concentrations of the (-UVA) part of the experiment.

Prediction of phototoxicity is supported if, in addition, the (+UVA) induced reduction in tissue viability shows a dose response relationship.


Note: It is a quite common observation for certain phototoxins, that a severe effect may be reduced again at higher doses. This is due to the UV absorbing properties of the chemical by which they act as UV filters if excessive doses are applied which remain on the stratum corneum.

ANNEX A: Procedure Steps


First day of testing (Wednesday)



Second day of testing



Third day of testing (Friday)



ANNEX B: Methods Documentation Sheet

ASSAY No.:..... DATE:.....

XLS file name:..... Test Chemical.....

Kit receipt

| | |
|----------------------------------|------------------|
| EpiDerm kit received (day/date): | Day used: |
| EpiDerm Lot no.: | Production date: |
| Epi-100 Assay medium Lot no.: | Expiration date: |
| MTT concentrate Lot no.: | Date: |
| MTT diluent Lot no.: | Date: |
| MTT extractant Lot no.: | Date: |
| Booked in by (ID): | |

PBS preparation (to be filled in only if PBS is prepared from concentrate / powder)

| | | |
|-------------------------|------------------|-------------|
| DPBS Lot no.: | Expiration date: | |
| Vol 10x DPBS: | Vol water: | Initial pH: |
| NaOH used to adjust pH: | | Final pH: |
| HCl used to adjust pH: | | Final pH: |
| Prepared by (ID): | | |

Incubator verification

| Incubator # | CO ₂ (%) | Temperature (°C) | Check water in reservoir (ü) | ID / date: |
|-------------|---------------------|------------------|-------------------------------|------------|
| | | | | |

Pipette verification (triplicate weightings)

Note: Perform pipette verification only once per week and refer to it in all assays of this week. But: If adjustable pipettes are used, check correct adjustment daily and mark with (ü).

| Verification | 0.9 ml | 300 µl | 200 µl | 20 µl | 50 µl |
|--------------|------------------------------|--------|--------|-------|-------|
| | H ₂ O weight (mg) | | | | |
| 1. | | | | | |
| 2. | | | | | |
| 3. | | | | | |

ID / date:

Preparation of test chemical and application

| | | concentration (%) |
|--------------------|--|-------------------|
| stock preparation: | | |
| 1. dilution: | | |
| 2. dilution: | | |
| 3. dilution: | | |
| 4. dilution: | | |
| 5. dilution: | | |

vehicle used (H₂O / oil):

homogenisation technique:

solution / suspension:

application volume (µl):

applied + pad or - pad:

Time protocols

| Procedure | Start | Stop | ID / Date: |
|---|-------|------|------------|
| 1 hr pre-incubation of tissues | | | |
| over night chemical application (incubator) | | | |
| 3 hrs MTT incubation | | | |
| Formazan extraction | | | |

Check plate photometer filter (ü)

| | |
|------------------------|--|
| reading filter: 570 nm | |
| reading filter: 540 nm | |

ID / Date:

Remarks

ANNEX C: Excel Spreadsheet

chemical: **Bergamotteoil**
 tissue no.: 1230 D
 exp no.: 77

solvent: oil
 date of start: 07.06.97
 irradiation: 6.10cm²
 application time: 21 hours


| | | | | mean |
|---------|-------|-------|-------|-------|
| control | 0.922 | 0.902 | 0.887 | 0.903 |
| | 1.006 | 1.062 | 1.032 | 1.047 |
| 0,1 | 1.042 | 1.04 | 1.038 | 1.04 |
| | 0.962 | 0.95 | 0.948 | 0.953 |
| 0,316 | 1.051 | 1.055 | 1.072 | 1.059 |
| | 0.938 | 0.902 | 0.907 | 0.915 |
| 1 | 0.972 | 0.96 | 0.940 | 0.957 |
| | 0.867 | 0.86 | 0.86 | 0.86 |
| 3.16 | 0.966 | 0.969 | 0.968 | 0.965 |
| | 1.065 | 1.069 | 1.051 | 1.06 |
| 10 | 0.907 | 0.915 | 0.904 | 0.919 |
| | 0.917 | 0.933 | 0.972 | 0.92 |

| | | | | mean |
|---------|-------|-------|-------|-------|
| control | 1.117 | 1.168 | 1.186 | 1.157 |
| | 0.884 | 0.884 | 0.886 | 0.884 |
| 0,1 | 1.079 | 1.075 | 1.088 | 1.083 |
| | 1.000 | 1.054 | 1.088 | 1.067 |
| 0,316 | 0.875 | 0.870 | 0.879 | 0.875 |
| | 0.070 | 0.030 | 0.070 | 0.043 |
| 1 | 0.694 | 0.686 | 0.600 | 0.659 |
| | 0.622 | 0.625 | 0.626 | 0.624 |
| 3.16 | 0.512 | 0.510 | 0.519 | 0.512 |
| | 0.571 | 0.568 | 0.571 | 0.570 |
| 10 | 0.547 | 0.575 | 0.571 | 0.570 |
| | 0.281 | 0.280 | 0.280 | 0.280 |


w/o UVA


| | mean | tissue [%] | % untreated control |
|---------|-------|------------|---------------------|
| control | 0.975 | 15.74 | 100 |
| 0,1 | 1.000 | 3.27 | 100 |
| 0,316 | 0.977 | 12.72 | 100 |
| 1 | 0.911 | 10.95 | 93 |
| 3.16 | 1.015 | 2.44 | 104 |
| 10 | 0.937 | 7.13 | 94 |

| | mean | tissue [%] | % untreated control |
|---------|-------|------------|---------------------|
| control | 1.022 | 23.28 | 100 |
| 0,1 | 1.075 | 7.40 | 105 |
| 0,316 | 0.050 | 3.31 | 0 |
| 1 | 0.610 | 4.53 | 60 |
| 3.16 | 0.201 | 14.33 | 28 |
| 10 | 0.505 | 19.07 | 37 |





ANNEX D: Positive Reference Data









ANNEX E: Negative Reference Data






ANNEX F: EPI-200 UVA-Sensitivity





The figures show four independent UV sensitivity experiments performed according to **2.3.1 "UVA Sensitivity of the EPI-200 tissues"**. The dose of 6 J/cm² used in the EpiDerm™ Phototoxicity Test is not cytotoxic in any of the experiments. In addition, the dose of 6 J/cm² is comparable to doses used in animal tests and has proved to be sufficient to activate phototoxins.


ANNEX G: Irradiance spectrum of the sun simulator



Note: The irradiance spectra of the SOL 3 and SOL 500 are nearly identical up to a wavelength of ~ 550 nm. In the longer wavelength range of visible light (>550nm-700nm) the SOL 500 irradiance decreases, whereas the irradiance of the SOL 3 remains at the same level. In the EU/COLIPA validation study this difference proved to irrelevant.

ADDENDUM (13 November 1997)

The spectrum (provided by Beiersdorf AG) shows the FORMAZAN absorption. It explains why the reference filter of 630 nm has been omitted. If the filter is not precise (e.g. 620 nm) the dynamics of the reading will be reduced by ~40%!!



Bibliography

- Api, A.M. (1997)

In vitro assessment of phototoxicity.

In Vitro Toxicology 10, 339-350

- Curren R.D., Southee J.A., Spielmann H., Liebsch M., Fentem J.H. and Balls M. (1995)
The role of prevalidation in the development, validation and acceptance of alternative methods. ECVAM Prevalidation Task Force Report 1.
Alternatives to Laboratory Animals (ATLA) 23, 211-217
- Edwards, S.M., Donally T.A., Sayre, R.M. Rheins, L.A., Spielmann, H. and Liebsch M. (1994)
Quantitative in vitro assessment of phototoxicity using a human skin model; Skin2.
Photodermatology, Photoimmunology and Photomedicine 10, 111-117
- Gerberick, G.F. and Ryan, C.A. (1990)
Use of UVB and UVA to induce and elicit contact photoallergy in the mouse.
Photodermatology, Photoimmunology and Photomedicine 7, 13-19
- Klausner, M., Kubilus, J., Richer, H.A. and P.J. Neal (1995)
UVB irradiation of an organotypic skin model, Epiderm™, results in significant release of cytokines.
The Toxicologist 15(1)
- Liebsch M., Barrabas C., Traue D. and Spielmann H. (1997)
Entwicklung eines neuen in vitro tests auf dermale Phototoxizität mit einem Modell menschlicher Epidermis (Epiderm™).
Alternatives to Animal Experimentation (ALTEX) 14, 165-174
- Liebsch M., Döring B., Donnelly T.A., Logemann P., Rheins L.A. and Spielmann H. (1995)
Application of the human dermal model Skin2 ZK 1350 to phototoxicity and skin corrosivity testing.
Toxicology In Vitro 9, 557-562
- Liebsch, M., Spielmann, H., Balls, M., Brand, M., Doering, B., Dupuis, J., Holzhütter, H.G., Klecak, G., L'Eplattenier, H., Lovell, W. W., Maurer, T., Moldenhauer, F., Moore, L., Pape, W. J. W., Pfannenbecker, U., Potthast, J., De Silva, O., Steiling, W., Willshaw, A. (1994)
First results of the EC/COLIPA validation project "in vitro phototoxicity testing".
In Vitro Skin Toxicology; Irritation, Phototoxicity, Sensitization. Serialtitle: Alternative Methods in Toxicology 10, 243-254
- Mosmann T. (1983)
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.
Journal of Immunological Methods 65, 55-63
- Perkins M.A., Osborne R. and G. R. Johnson (1996)
Development of an in vitro Method for Skin Corrosion Testing.
Fundamental and Applied Toxicology 31, 9-18
- Rouget R., Cohen C. and A. Rougier (1994)
A reconstituted human epidermis to assess cutaneous irritation, photoirritation and photoprotection in vitro.
In Vitro Skin Toxicology; Irritation, Phototoxicity, Sensitization. Serialtitle: Alternative Methods in Toxicology 10, 141-149
- Spielmann, H., Balls, M., Dupuis, J., Pape, W.J.W., De Silva, O., Holzhütter, H.G., Gerberick, F., Liebsch, M., Lovell, W.W., Pfannenbecker. (1998a)
A Study on UV Filter Chemicals from Annex VII of the EU Directive 76/768/EEC in the 3T3 NRU In Vitro Phototoxicity Test.
Alternatives to Laboratory Animals (ATLA) 26, 679-708
- Spielmann, H., Balls, M., Dupuis, J., Pape, W.J.W., Pechovitch, G., De Silva, O., Holzhütter, H.G., Clothier, R., Desolle, P., Gerberick, f., Liebsch, M., Lovell, W.W., Maurer, T., Pfannenbecker, U., Potthast, J.M., csato, M., Sladowski, D., Steiling, W. and Brantom, P. (1998b)
EU/COLIPA "In Vitro phototoxicity" validation study, results of phase II (blind trial), part 1: the 3T3 NRU phototoxicity test.
Toxicology In Vitro, 305-327
- Spielmann, H., Liebsch, M., Pape, W.J.W., Balls, M. Dupius, J., Klecak, G., Lovell, W.W., Maurer, De Silva, O., Steiling, W. (1995)
The EEC COLIPA in vitro photoirritancy program: results of the first stage of validation. In: Irritant Dermatitis: New clinical and experimental aspects. Eds. P. Elsner and H.I. Maibach.